Teva Wins Ruling Tossing $235 Million Glaxo Drug Verdict
- Generic of Coreg didn’t infringe Glaxo patent, judge rules
- Coreg reduces chance of death from congestive heart failure
Employees wear protective clothing as they pour chemicals into a container in the tablet production plant at Teva Pharmaceutical Industries Ltd.'s headquarters in Jerusalem, Israel, on Sept. 19, 2011.
Photographer: Adam Reynolds/Bloomberg
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. won a court ruling tossing a $235 million verdict over its copy of GlaxoSmithKline Plc’s Coreg heart drug.
Teva’s generic version didn’t infringe a Glaxo patent, U.S. District Judge Leonard P. Stark in Wilmington, Delaware, ruled Wednesday.